Skip to Content
Merck

SML0465

Symadex

≥98% (HPLC)

Synonym(s):

5-[[2-(Diethylamino)ethyl]amino]-8-hydroxy-6H-Imidazo[4,5,1-de]acridin-6-one, C-1311, C1311

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C20H22N4O2
CAS Number:
138154-39-9
Molecular Weight:
350.41
NACRES:
NA.77
PubChem Substance ID:
329824743
UNSPSC Code:
12352200
MDL number:
MFCD00947296

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

InChI

1S/C20H22N4O2/c1-3-23(4-2)10-9-21-15-6-7-16-19-18(15)20(26)14-11-13(25)5-8-17(14)24(19)12-22-16/h5-8,11-12,21,25H,3-4,9-10H2,1-2H3

SMILES string

CCN(CC)CCNc1ccc2ncn3-c4ccc(O)cc4C(=O)c1c23

InChI key

CUNDRHORZHFPLY-UHFFFAOYSA-N

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 10 mg/mL (clear solution; warmed)

storage temp.

2-8°C

Quality Level

100

Gene Information

human ... FLT3(2322), TOP2A(7153), TOP2B(7155)

Related Categories

Biochem/physiol Actions

Symadex is a FLT3 and topoisomerase-II inhibitor; ABCG2 substrate; cell cycle modulator.
Symadex is an FMS-like tyrosine kinase 3 (FLT3) and topoisomerase-II inhibitor; ABCG2 substrate; cell cycle modulator.

Features and Benefits

This compound is a featured product for Kinase Phosphatase Biology research. Click here to discover more featured Kinase Phosphatase Biology products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound is featured on the PDGFR page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H302

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000025050
092M4602V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Jaroslaw Dziegielewski et al.
Biochemical pharmacology, 63(9), 1653-1662 (2002-05-15)
Imidazoacridinones (IA) are a class of antitumor agents which includes C-1311, an interesting drug in clinical trials. This study investigated the mechanism of IA binding to DNA for a series of 13 analogs that differ in their cytotoxic potency. Using
Magdalena Hyzy et al.
Biochemical pharmacology, 69(5), 801-809 (2005-02-16)
In this study, we investigated the cell death process induced by imidazoacridone C-1311 (Symadex) in HT-29 human colon carcinoma cells which have been shown to be preferentially sensitive to this compound in experimental tumour models both in vitro and in
Agnieszka Potega et al.
Drug metabolism and disposition: the biological fate of chemicals, 39(8), 1423-1432 (2011-05-11)
5-Diethylaminoethylamino-8-hydroxyimidazoacridinone (C-1311) is an antitumor agent that is also active against autoimmune diseases. The intention of the present studies was to elucidate the role of selected liver enzymes in metabolism of C-1311 and the less active 8-methyl derivative, 5-diethylaminoethylamino-8-methoxyimidazoacridinone (C-1330).
Marie Suggitt et al.
International journal of oncology, 29(6), 1493-1499 (2006-11-08)
We describe a modified hollow fibre assay (HFA) for investigating the potential of novel molecules as pharmaceutical agents. In particular the assay provides drug/target interaction data that can facilitate the selection of lead compounds for further evaluation in more sophisticated
Anna Skwarska et al.
Apoptosis : an international journal on programmed cell death, 12(12), 2245-2257 (2007-10-10)
Imidazoacridinone C-1311 is a DNA-targeting antitumor intercalator/alkylator currently undergoing Phase II clinical trials. Here, we elucidated the sequence of death responses to C-1311 in human leukemia MOLT4 cells using drug concentration (30 nM) that causes near complete cell growth inhibition
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service